CN102917708B - 制备大环内酯和酮内酯及其中间体的方法 - Google Patents

制备大环内酯和酮内酯及其中间体的方法 Download PDF

Info

Publication number
CN102917708B
CN102917708B CN201180026739.4A CN201180026739A CN102917708B CN 102917708 B CN102917708 B CN 102917708B CN 201180026739 A CN201180026739 A CN 201180026739A CN 102917708 B CN102917708 B CN 102917708B
Authority
CN
China
Prior art keywords
compound
formula
acid addition
addition salt
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180026739.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102917708A (zh
Inventor
D·E·佩雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Priority to CN201510604701.0A priority Critical patent/CN105198944B/zh
Publication of CN102917708A publication Critical patent/CN102917708A/zh
Application granted granted Critical
Publication of CN102917708B publication Critical patent/CN102917708B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180026739.4A 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法 Expired - Fee Related CN102917708B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510604701.0A CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34666410P 2010-05-20 2010-05-20
US61/346,664 2010-05-20
PCT/US2011/037330 WO2011146829A1 (en) 2010-05-20 2011-05-20 Processes for preparing macrolides and ketolides and intermediates therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510604701.0A Division CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Publications (2)

Publication Number Publication Date
CN102917708A CN102917708A (zh) 2013-02-06
CN102917708B true CN102917708B (zh) 2015-11-25

Family

ID=44992076

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180026739.4A Expired - Fee Related CN102917708B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法
CN201510604701.0A Expired - Fee Related CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510604701.0A Expired - Fee Related CN105198944B (zh) 2010-05-20 2011-05-20 制备大环内酯和酮内酯及其中间体的方法

Country Status (15)

Country Link
US (4) US9051346B2 (enExample)
EP (1) EP2571506B1 (enExample)
JP (1) JP6184319B2 (enExample)
KR (1) KR101945324B1 (enExample)
CN (2) CN102917708B (enExample)
AU (1) AU2011255464C1 (enExample)
BR (1) BR112012029586A2 (enExample)
CA (1) CA2799937A1 (enExample)
DK (1) DK2571506T3 (enExample)
ES (1) ES2636948T3 (enExample)
IL (1) IL223161A0 (enExample)
PL (1) PL2571506T3 (enExample)
RU (1) RU2608390C2 (enExample)
SI (1) SI2571506T1 (enExample)
WO (1) WO2011146829A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
IN2014DN08939A (enExample) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CN103897002A (zh) * 2012-12-31 2014-07-02 菏泽市方明制药有限公司 一种粗品硫氰酸红霉素制备红霉素a9-肟的方法
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
WO2016057798A1 (en) * 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
CN106554381A (zh) * 2015-09-25 2017-04-05 苏州鹏旭医药科技有限公司 酮内酯类抗生素中间体及其制备方法和应用
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1343216A (zh) * 1999-04-08 2002-04-03 北陆制药株式会社 红霉素衍生物
WO2003004509A2 (en) * 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US6515116B2 (en) * 2000-03-15 2003-02-04 Hanmi Pharm. Co., Method of preparing form II crystals of clarithromycin

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
ATE296308T1 (de) 1996-09-04 2005-06-15 Abbott Lab 6-o-substituierte ketoliden mit antibakteriellen wirkung
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
ID24529A (id) 1997-06-11 2000-07-20 Pfizer Prod Inc Turunan-turunan 9-oksima eritromisin
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
TR200102129T2 (tr) 1998-12-10 2002-01-21 Pfizer Products Inc. Karbamat ve karbazat ketolid antibiyotikleri.
KR20020002380A (ko) 1999-01-27 2002-01-09 실버스타인 아써 에이. 케톨라이드 항생물질
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
CN1373767A (zh) 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
ATE340183T1 (de) 1999-04-16 2006-10-15 Kosan Biosciences Inc Antiinfektiöse makrolidderivate
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
ES2261735T3 (es) 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
MXPA04008173A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
DK2226316T3 (en) 2002-05-30 2016-04-11 Scripps Research Inst Copper catalyzed ligation of azides and acetylenes
IL165291A0 (en) 2002-06-17 2005-12-18 Epigenesis Pharmaceuticals Llc Dihydrate dehydroepiandorosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
CA2523134A1 (en) 2003-04-25 2004-11-11 Chiron Corporation Pyridyl substituted ketolide antibiotics
HRP20070094T3 (hr) * 2003-05-13 2008-05-31 Glaxo Group Limited NOVI 14- i 15-EROČLANI PRSTENASTI SPOJEVI
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
EP1742957B1 (en) 2004-04-28 2007-09-12 Alembic Limited Process for the preparation of telithromycin
ES2331739T3 (es) * 2004-05-06 2010-01-14 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolidos que contienen enlaces ester utiles para el tratamiento de infecciones microbianas.
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
GB0424958D0 (en) * 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) * 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
CN2756842Y (zh) * 2004-11-12 2006-02-08 胡济荣 沙滩车用一体化发动机
DE602006006546D1 (de) 2005-01-14 2009-06-10 Glaxosmithkline Zagreb 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung
WO2006075256A2 (en) 2005-01-14 2006-07-20 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
CA2614412A1 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
EP2023721A2 (en) 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
CA2703179C (en) * 2007-10-23 2016-06-07 Transave, Inc. Liposomal vancomycin formulations
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
HRP20160222T1 (hr) * 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
JP5711352B2 (ja) 2010-03-22 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用
CN102917708B (zh) * 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
CA2812044A1 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
IN2014DN08939A (enExample) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1343216A (zh) * 1999-04-08 2002-04-03 北陆制药株式会社 红霉素衍生物
US6515116B2 (en) * 2000-03-15 2003-02-04 Hanmi Pharm. Co., Method of preparing form II crystals of clarithromycin
WO2003004509A2 (en) * 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity

Also Published As

Publication number Publication date
AU2011255464C1 (en) 2017-02-23
CN102917708A (zh) 2013-02-06
SI2571506T1 (sl) 2017-12-29
ES2636948T3 (es) 2017-10-10
EP2571506A4 (en) 2014-04-02
CN105198944B (zh) 2018-06-01
WO2011146829A1 (en) 2011-11-24
CN105198944A (zh) 2015-12-30
BR112012029586A2 (pt) 2016-08-02
EP2571506B1 (en) 2017-05-10
JP6184319B2 (ja) 2017-08-23
AU2011255464B2 (en) 2016-06-16
AU2011255464A1 (en) 2012-12-13
CA2799937A1 (en) 2011-11-24
IL223161A0 (en) 2013-02-03
RU2608390C2 (ru) 2017-01-18
US20130066056A1 (en) 2013-03-14
KR20130120374A (ko) 2013-11-04
RU2012150753A (ru) 2014-06-27
US20150232500A1 (en) 2015-08-20
KR101945324B1 (ko) 2019-02-07
DK2571506T3 (en) 2017-08-28
HK1181672A1 (zh) 2013-11-15
EP2571506A1 (en) 2013-03-27
HK1218919A1 (zh) 2017-03-17
US20200087335A1 (en) 2020-03-19
US9051346B2 (en) 2015-06-09
PL2571506T3 (pl) 2017-10-31
JP2013527187A (ja) 2013-06-27
US20190048035A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
CN102917708B (zh) 制备大环内酯和酮内酯及其中间体的方法
US20190241602A1 (en) Process for the preparation of macrolide antibacterial agents
JP2015038095A (ja) 抗菌活性を有する６−ｏ−置換ケトリド
PL213731B1 (pl) Sposób wytwarzania pochodnej 4"-podstawionej-9-deoksy-9A-aza-9A-homoerytromecyny
HUP0004085A2 (hu) A 9a-azaleidek csoportjához tartozó, új 3,6-hemiketálszármazékok
EP0124216B1 (en) C-20- and c-23-modified macrolide derivatives
CA1234807A (en) C-20- and c-23-modified macrolide derivatives
JP2001515844A (ja) ３−デスクラジノース６−ｏ−置換エリスロマイシン誘導体
HK1218919B (en) Processes for preparing macrolides and ketolides and intermediates therefor
HK1181672B (en) Processes for preparing macrolides and ketolides and intermediates therefor
BG62333B1 (bg) Нови съединения от клас секомакролиди и секоазалиди и методза получаването им
US7410952B2 (en) Derivatives of azithromycin
HK1183432B (en) Processes for preparing macrolides and ketolides and intermediates therefor
HK1183432A (en) Processes for preparing macrolides and ketolides and intermediates therefor
US7435805B2 (en) O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
JP2001072699A (ja) マクロライド系化合物
WO1998040393A1 (fr) Nouveaux derives du mycaminosyltylonolide
HUT74073A (en) New compounds of the secomacrolide and secoazalide class and a process for the preparation thereof
JP2007223900A (ja) ６−ｏ−置換ケトライド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181672

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1181672

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20200520